Evaxion Biotech Stock Forum

$Evaxion Biotech (EVAX.US)$
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
Evaxion Biotech A/S (NASDAQ: EVAX) has unveiled improved performance of its key AI-Immunology™ building block, EvaxMHC, at the 32nd Intelligent Systems for Molecular Biology conference. The advancements in EvaxMHC are expected to enhance Evaxion's ability to accurately predict vaccine targets for personalized and precision vaccines in cancer and infect...

$Evaxion Biotech (EVAX.US)$     Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method.                  Evaxion, On Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method, Says An International Preliminary Report on Patentability Indicates 'Promising Prospects for Obtaining Granted Patents and Protecting the Invention'

$Evaxion Biotech (EVAX.US)$ Evaxion Biotech A/S: One-Year Clinical Efficacy Readout From Phase 2 Study Is on Track for Q3 2024

$Evaxion Biotech (EVAX.US)$
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
Evaxion has published Phase 1 study data for its AI-designed personalized cancer vaccine, EVX-01, in the Journal for ImmunoTherapy of Cancer. The study showed a 67% objective response rate (ORR) in patients with metastatic melanoma, with eight out of 12 patients showing clinical responses — six partial...

$Evaxion Biotech (EVAX.US)$ Evaxion Presents Positive and Validating Immune Data From Ongoing Phase 2 Trial With AI-Designed Evx-01 Vaccine at the Asco Annual Meeting 2024

$Evaxion Biotech (EVAX.US)$
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
JUNE 01, 2024
Poster Details:
Abstract Title:“Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma”
Abstract #:9561
Poster Bd #:345 
Track:Melanoma/Skin Cancers
Location:Hall A – McCormick Pla...

$Evaxion Biotech (EVAX.US)$ Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

$Evaxion Biotech (EVAX.US)$ Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies.
MT Newswires· 1 min ago

$Evaxion Biotech (EVAX.US)$ Evaxion Biotech beat estimated earnings by 90.0%, that's great news!!